OptiBIRTH: a cluster randomised trial of a complex intervention to increase vaginal birth after caesarean section.
Journal
BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799
Informations de publication
Date de publication:
06 Mar 2020
06 Mar 2020
Historique:
received:
19
03
2019
accepted:
20
02
2020
entrez:
7
3
2020
pubmed:
7
3
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Despite evidence supporting the safety of vaginal birth after caesarean section (VBAC), rates are low in many countries. OptiBIRTH investigated the effects of a woman-centred intervention designed to increase VBAC rates through an unblinded cluster randomised trial in 15 maternity units with VBAC rates < 35% in Germany, Ireland and Italy. Sites were matched in pairs or triplets based on annual birth numbers and VBAC rate, and randomised, 1:1 or 2:1, intervention versus control, following trial registration. The intervention involved evidence-based education of clinicians and women with one previous caesarean section (CS), appointment of opinion leaders, audit/peer review, and joint discussions by women and clinicians. Control sites provided usual care. Primary outcome was annual hospital-level VBAC rates before the trial (2012) versus final year of the trial (2016). Between April 2014 and October 2015, 2002 women were recruited (intervention 1195, control 807), with mode-of-birth data available for 1940 women. The OptiBIRTH intervention was feasible and safe across hospital settings in three countries. There was no statistically significant difference in the change in the proportion of women having a VBAC between intervention sites (25.6% in 2012 to 25.1% in 2016) and control sites (18.3 to 22.3%) (odds ratio adjusted for differences between intervention and control groups (2012) and for homogeneity in VBAC rates at sites in the countries: 0.87, 95% CI: 0.67, 1.14, p = 0.32 based on 5674 women (2012) and 5284 (2016) with outcome data. Among recruited women with birth data, 4/1147 perinatal deaths > 24 weeks gestation occurred in the intervention group (0.34%) and 4/782 in the control group (0.51%), and two uterine ruptures (one per group), a rate of 1:1000. Changing clinical practice takes time. As elective repeat CS is the most common reason for CS in multiparous women, interventions that are feasible and safe and that have been shown to lead to decreasing repeat CS, should be promoted. Continued research to refine the best way of promoting VBAC is essential. This may best be done using an implementation science approach that can modify evidence-based interventions in response to changing clinical circumstances. The OptiBIRTH trial was registered on 3/4/2013. Trial registration number ISRCTN10612254.
Sections du résumé
BACKGROUND
BACKGROUND
Despite evidence supporting the safety of vaginal birth after caesarean section (VBAC), rates are low in many countries.
METHODS
METHODS
OptiBIRTH investigated the effects of a woman-centred intervention designed to increase VBAC rates through an unblinded cluster randomised trial in 15 maternity units with VBAC rates < 35% in Germany, Ireland and Italy. Sites were matched in pairs or triplets based on annual birth numbers and VBAC rate, and randomised, 1:1 or 2:1, intervention versus control, following trial registration. The intervention involved evidence-based education of clinicians and women with one previous caesarean section (CS), appointment of opinion leaders, audit/peer review, and joint discussions by women and clinicians. Control sites provided usual care. Primary outcome was annual hospital-level VBAC rates before the trial (2012) versus final year of the trial (2016). Between April 2014 and October 2015, 2002 women were recruited (intervention 1195, control 807), with mode-of-birth data available for 1940 women.
RESULTS
RESULTS
The OptiBIRTH intervention was feasible and safe across hospital settings in three countries. There was no statistically significant difference in the change in the proportion of women having a VBAC between intervention sites (25.6% in 2012 to 25.1% in 2016) and control sites (18.3 to 22.3%) (odds ratio adjusted for differences between intervention and control groups (2012) and for homogeneity in VBAC rates at sites in the countries: 0.87, 95% CI: 0.67, 1.14, p = 0.32 based on 5674 women (2012) and 5284 (2016) with outcome data. Among recruited women with birth data, 4/1147 perinatal deaths > 24 weeks gestation occurred in the intervention group (0.34%) and 4/782 in the control group (0.51%), and two uterine ruptures (one per group), a rate of 1:1000.
CONCLUSIONS
CONCLUSIONS
Changing clinical practice takes time. As elective repeat CS is the most common reason for CS in multiparous women, interventions that are feasible and safe and that have been shown to lead to decreasing repeat CS, should be promoted. Continued research to refine the best way of promoting VBAC is essential. This may best be done using an implementation science approach that can modify evidence-based interventions in response to changing clinical circumstances.
TRIAL REGISTRATION
BACKGROUND
The OptiBIRTH trial was registered on 3/4/2013. Trial registration number ISRCTN10612254.
Identifiants
pubmed: 32138712
doi: 10.1186/s12884-020-2829-y
pii: 10.1186/s12884-020-2829-y
pmc: PMC7059398
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
143Subventions
Organisme : Medical Research Council
ID : G0901530
Pays : United Kingdom
Références
Lancet. 2018 Oct 13;392(10155):1341-1348
pubmed: 30322584
BJOG. 2016 Apr;123(5):745-53
pubmed: 26331389
Trials. 2018 Jan 05;19(1):9
pubmed: 29304837
Lancet. 2018 Oct 13;392(10155):1349-1357
pubmed: 30322585
Birth. 2017 Jun;44(2):153-160
pubmed: 27917532
Br J Obstet Gynaecol. 1995 Feb;102(2):101-6
pubmed: 7756199
Midwifery. 2015 Jul;31(7):657-63
pubmed: 25931275
Midwifery. 2019 Dec;79:102536
pubmed: 31561129
Trials. 2015 Nov 30;16:542
pubmed: 26620402
Int J Clin Pract. 2001 May;55(4):240-2
pubmed: 11406908
Midwifery. 2019 Jul;74:36-43
pubmed: 30925415
BMC Pregnancy Childbirth. 2013 Apr 03;13:83
pubmed: 23551909
PLoS One. 2016 Feb 05;11(2):e0148343
pubmed: 26849801
J Eval Clin Pract. 2019 Dec;25(6):1113-1120
pubmed: 31338953
BMC Pregnancy Childbirth. 2018 Apr 11;18(1):92
pubmed: 29642858
Soc Sci Med. 2007 Jun;64(11):2272-84
pubmed: 17395349
Women Birth. 2017 Dec;30(6):481-490
pubmed: 28545775
Br J Cancer. 2011 Mar 29;104(7):1057-8
pubmed: 21448174
BMJ. 2007 Nov 17;335(7628):1025
pubmed: 17977819
BMC Pregnancy Childbirth. 2016 Nov 10;16(1):350
pubmed: 27832743
Cochrane Database Syst Rev. 2013 Dec 10;(12):CD004224
pubmed: 24323886
Obstet Gynecol. 2010 Jun;115(6):1267-78
pubmed: 20502300
BMC Pregnancy Childbirth. 2015 Feb 05;15:16
pubmed: 25652550
Med J Aust. 2013 Sep 2;199(5):348-53
pubmed: 23992192
CMAJ. 1995 Nov 15;153(10):1423-31
pubmed: 7585368
BMC Pregnancy Childbirth. 2015 Aug 28;15:196
pubmed: 26314295
BJOG. 2016 Mar;123(4):559-68
pubmed: 25753683
J Obstet Gynaecol Can. 2013 May;35(5):434-443
pubmed: 23756274
Obstet Gynecol. 2010 Aug;116(2 Pt 1):450-63
pubmed: 20664418
Women Birth. 2019 Aug 21;:
pubmed: 31445846
Ir Med J. 2016 Dec 12;109(10):482
pubmed: 28644587
BMC Pregnancy Childbirth. 2015 Aug 19;15:179
pubmed: 26285692
NIH Consens State Sci Statements. 2010 Mar 10;27(3):1-42
pubmed: 20228855
Reprod Health. 2015 Jun 21;12:57
pubmed: 26093498
BMC Pregnancy Childbirth. 2012 Aug 21;12:85
pubmed: 22909230
Qual Health Res. 2017 Feb;27(3):325-340
pubmed: 26531882
PLoS Med. 2012;9(3):e1001184
pubmed: 22427745